- $939.37m
- $464.56m
- $297.61m
- 82
- 21
- 94
- 72
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 131 | 170 | 229 | 261 | 298 |
Cost of Revenue | |||||
Gross Profit | 65.7 | 92.8 | 123 | 135 | 153 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 144 | 177 | 285 | 371 | 374 |
Operating Profit | -13.9 | -6.81 | -55.9 | -109 | -76.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.7 | -10.3 | -178 | -98.7 | -53.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.2 | -11.3 | -179 | -105 | -59 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.2 | -11.3 | -179 | -105 | -59 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.2 | -11.3 | -179 | -105 | -59 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.09 | -0.072 | -2.35 | -0.623 | -0.333 |
Dividends per Share |